



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



**June 27, 2018**

<b>To</b> <b>The Department of Corporate Services</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 <b>Security Code: 540596</b>	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 <b>Symbol: ERIS</b>
---	--

**SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)**

Dear Sir/Madam,

We refer to our intimation letter dated 1<sup>st</sup> December, 2017 pursuant to Regulation 30 of SEBI (LODR), 2015 informing that the Company had entered into a Term Loan Facility Agreement with Axis Bank Limited ("Lender") dated 30<sup>th</sup> November, 2017 for part financing the acquisition of business undertaking of the domestic formulation business containing brands / trademarks / assets of M/s Strides Shasun Limited.

The Company hereby notifies the completion of execution of documents aimed at creating securities in favour of the Lenders as per the terms appearing in the Sanction letter dated 30<sup>th</sup> November, 2017 which have been summarized at point 12 of Annexure-A to the said disclosure.

Thanking You,

**For Eris Lifesciences Limited**

**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**

**Registered & Corporate Office:**

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867